Infliximab in inflammatory bowel disease. Is premedication necessary?

Melsheimer, 2019, Remicade® (infliximab): 20 years of contributions to science and medicine, Biologics, 13, 139 Targan, 1997, A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s disease cA2 Study Group, N Engl J Med, 337, 1029, 10.1056/NEJM199710093371502 Cheifetz, 2003, The incidence and management of infusion reactions to infliximab: a large center experience, Am J Gastroenterol, 98, 1315, 10.1111/j.1572-0241.2003.07457.x Lichtenstein, 2015, Infliximab-related infusion reactions: systematic review, J Crohns Colitis, 9, 806, 10.1093/ecco-jcc/jjv096 Wasserman, 2004, Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number, J Rheumatol, 31, 1912 Kelsall, 2012, Safety of infliximab treatment in patients with rheumatoid arthritis in a real-world clinical setting: description and evaluation of infusion reactions, J Rheumatol, 39, 1539, 10.3899/jrheum.110956 Choquette, 2015, Incidence and Management of infusion reactions to infliximab in a prospective real-world Community Registry, J Rheumatol, 42, 1105, 10.3899/jrheum.140538 Duron, 2015, Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy, Eur J Gastroenterol Hepatol, 27, 705, 10.1097/MEG.0000000000000354 Checkley, 2019, Incidence and management of infusion reactions to infliximab in an alternate care setting, Dig Dis Sci, 64, 855, 10.1007/s10620-018-5319-6 Vultaggio, 2010, Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions, Allergy, 65, 657, 10.1111/j.1398-9995.2009.02280.x Steenholdt, 2011, Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease, Aliment Pharmacol Ther, 34, 51, 10.1111/j.1365-2036.2011.04682.x Vultaggio, 2011, Immediate adverse reactions to biologicals: from pathogenic mechanisms to prophylactic management, Curr Opin Allergy Clin Immunol, 11, 262, 10.1097/ACI.0b013e3283464bcd O’Meara, 2014, Antibodies to infliximab and risk of infections reactions in patients with Inflammatory Bowel Disease: a systematic review and meta-analysis, Inflamm Bowel Dis, 20, 1, 10.1097/01.MIB.0000436951.80898.6d Bermejo, 2008, Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab, Gastroenterol Hepatol, 31, 629, 10.1016/S0210-5705(08)75809-6 Bartoli, 2016, Premedication prevents infusion reactions and improves retention rate during infliximab treatment, Clin Rheumatol, 35, 2841, 10.1007/s10067-016-3351-5 Picoraro, 2017, Premedication use before infliximab administration: a cross-sectional analysis, Inflamm Bowel Dis, 23, 174, 10.1097/MIB.0000000000001002 Ricart, 2001, Infliximab for Crohn’s disease in clinical practice at the Mayo Clinic: the first 100 patients, Am J Gastroenterol, 96, 722, 10.1111/j.1572-0241.2001.03612.x Jacobstein, 2005, Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium, Inflamm Bowel Dis, 11, 442, 10.1097/01.MIB.0000158166.88238.ea Keshavarzian, 2007, A multicenter retrospective experience of infliximab in Crohn’s disease patients: infusion reaction rates and treatment persistency, Gastroenterol Hepatol, 3, 381 Mantzaris, 2009, A pilot study comparing hydrocortisone premedication to oncomitant azathioprina treatment in preventing loss of response to infliximab, Eur J Gastroenterol Hepatol, 21, 1042, 10.1097/MEG.0b013e32832937e3 Lee, 2011, A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study, Aliment Pharmacol Ther, 34, 181, 10.1111/j.1365-2036.2011.04699.x Farrell, 2003, Intravenous hydrocortisone premedication infliximab in Crohn’s disease: a randomized controlled trial, Gastroenterology, 124, 917, 10.1053/gast.2003.50145 Gold, 2017, Premedication use in preventing acute infliximab infusion reactions in patients with Inflammatory Bowel Disease: a single center cohort study, Inflamm Bowel Dis, 23, 1882, 10.1097/MIB.0000000000001189 Hutsell, 2017, Frequency of severe infusion reactions associated with outpatient infusion of infliximab without premedications, J Pediatr Gastroenterol Nutr, 65, 430, 10.1097/MPG.0000000000001535 Fumery, 2019, Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: a systematic review and meta-analysis, Dig Liver Dis, 51, 484, 10.1016/j.dld.2018.12.002 van Wassenaer, 2019, Premedication with intravenous steroids does not influence the incidence of reactions following infliximab infusions in pediatric Inflammatory Bowel Disease patients-a case-control study, Eur J Clin Pharmacol, 75, 1445, 10.1007/s00228-019-02715-z Lecluse, 2008, Review and expert opinion on prevention and treatment of infliximab-related infusion reactions, Br J Dermatol, 159, 527, 10.1111/j.1365-2133.2008.08728.x Domenech, 2010, Infliximab reintroduction is not associated to a higher rate of immune-related adverse effects in patients with inflammatory bowel disease initially treated with a three-infusion induction regimen, J Clin Gastroenterol, 44, 34, 10.1097/MCG.0b013e3181962dfa Rubin, 2019, Restarting biologic agents after a drug holiday, Gastroenterol Hepatol (NY), 15, 612 Mourad, 2015, Adverse reactions to infliximab and the outcome of desensitization, Ann Allergy Asthma Immunol, 115, 143, 10.1016/j.anai.2015.06.004 Lamb, 2019, British Society of Gastroenterology consensus guidelines on the management of Inflammatory Bowel Disease in adults, Gut, 68, s1, 10.1136/gutjnl-2019-318484 Papamichael, 2019, Infliximab in inflammatory bowel disease, Ther Adv Chronic Dis, 10, 10.1177/2040622319838443 Hossain, 2020, Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in Inflammatory Bowel Disease, Scand J Gastroenterol, 55, 178, 10.1080/00365521.2020.1722738 Ungaro, 2020, Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease, Aliment Pharmacol Ther, 51, 831, 10.1111/apt.15685 Hanauer, 2002, Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial, Lancet, 359, 1541, 10.1016/S0140-6736(02)08512-4 Larsen, 2019, Premedication with corticosteroids does not impact the pharmacokinetics of infliximab in Inflammatory Bowel Disease irrespective of azathioprine cotreatment, Eur J Gastroenterol Hepatol, 31, 964, 10.1097/MEG.0000000000001440 Baert, 2014, Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy, Clin Gastroenterol Hepatol, 12, 1474, 10.1016/j.cgh.2014.01.033 Franca, 2019, Therapeutic drug monitoring to improve outcome of anti-TNF drugs in pediatric Inflammatory Bowel Disease, Expert Opin Drug Metab Toxicol, 15, 527, 10.1080/17425255.2019.1630378 Al Sulais, 2020, Biosimilars to antitumor necrosis factor agents in Inflammatory Bowel Disease, Biologics, 10, 1 Shivaji, 2019, Review article: managing the adverse events caused by anti-TNF therapy in Inflammatory Bowel Disease, Aliment Pharmacol Ther, 49, 664, 10.1111/apt.15097 Fardet, 2007, Corticosteroid-induced adverse events in adults: frequency, screening and prevention, Drug Saf, 30, 861, 10.2165/00002018-200730100-00005 Simons, 2011, Histamine and H1-antihistamines: celebrating a century of progress, J Allergy Clin Immunol, 128, 1139, 10.1016/j.jaci.2011.09.005 Bálint, 2017, Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in Inflammatory Bowel Disease: results from Central European nationwide cohort, Expert Opin Drug Saf, 16, 885, 10.1080/14740338.2017.1323330